Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar:56:162-171.
doi: 10.1016/j.ejca.2015.12.022. Epub 2016 Feb 12.

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Liza C Villaruz  1 , Mark A Socinski  2
Affiliations
Review

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Liza C Villaruz et al. Eur J Cancer. 2016 Mar.

Abstract

Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC.

Keywords: Carboplatin; Elderly; Nab-paclitaxel; Neuropathy; Non-small cell lung cancer (NSCLC); Squamous cell histology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

Liza Villaruz has no conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
Overall response rate of nab-paclitaxel/carboplatin (nab-PC) and solvent-based paclitaxel/carboplatin (sb-PC) on the basis of independent assessment in a randomized phase III clinical trial comparing nab-PC versus sb-PC in newly diagnosed advanced non-small cell lung cancer patients, in the intention-to-treat (ITT) population and by histology.
Fig. 2
Fig. 2
Composite change for the Functional Assessment of Cancer Therapy-Taxane subscale at baseline and prior to dosing on day 1 of each cycle on a randomized phase III clinical trial comparing nab-paclitaxel/carboplatin (nab-PC) versus solvent-based paclitaxel/carboplatin (sb-PC) in patients with newly diagnosed advanced non-small cell lung cancer. Larger bars represent greater deteriorations from baseline as perceived by patients. Reprinted with permission from J Thorac Oncol. 2014;9: 83–90.
Fig. 3
Fig. 3
Kaplan–Meier curves of progression-free survival (top) and overall survival (OS, bottom) in the elderly (≥70 years of age) patients treated on a randomized phase III clinical trial comparing nab-paclitaxel/carboplatin (nab-PC) versus solvent-based paclitaxel/carboplatin (sb-PC) in patients with newly diagnosed advanced non-small cell lung cancer. Reprinted with permission from Annals of Oncology 24: 314–321, 2013.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
    1. Burdett S, et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–25. - PMC - PubMed
    1. Socinski MA, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl 5):e341S–68S. - PMC - PubMed
    1. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8. - PubMed
    1. Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51. - PubMed

MeSH terms